|Dr. Eric A. Rose M.D.||Exec. Chairman||2.22M||N/A||66|
|Dr. Phillip Louis Gomez III, Ph.D.||Chief Exec. Officer and Director||162.5k||N/A||50|
|Mr. Daniel J. Luckshire||Chief Financial Officer, Exec. VP and Sec.||1.68M||N/A||46|
|Dr. Dennis E. Hruby Ph.D.||Chief Scientific Officer and VP||1.98M||N/A||65|
|Ms. Robin E. Abrams J.D.||Chief Admin. Officer and Gen. Counsel||916.89k||N/A||53|
SIGA Technologies, Inc. engages in the development and commercialization of solutions for unmet medical needs and biothreats in the United States. Its lead product is TPOXX, an orally administered antiviral drug for treating orthopoxvirus infections. SIGA Technologies, Inc. was founded in 1995 and is headquartered in New York, New York.
SIGA Technologies, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.